PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
10.36%
Positive net income growth while Biotechnology median is negative at -1.82%. Peter Lynch would view it as a strong advantage vs. struggling peers.
-22.93%
D&A shrinks yoy while Biotechnology median is 0.00%. Seth Klarman would see a short-term earnings benefit if capacity is sufficient.
18.38%
Deferred tax growth of 18.38% while Biotechnology median is zero at 0.00%. Walter Schloss would see a difference that might matter for future cash flow if significant.
-40.28%
SBC declines yoy while Biotechnology median is 0.00%. Seth Klarman would see a near-term advantage in less dilution unless new hires are needed.
112.09%
Under 50% of Biotechnology median of 5.80% or exceeding it in the negative sense. Jim Chanos would suspect a bigger working capital drain if growth is not justified by sales.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
86.72%
AP growth of 86.72% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or credit policies affecting the difference.
300.21%
Growth of 300.21% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or unusual one-time factors behind the difference.
-40.28%
Other non-cash items dropping yoy while Biotechnology median is 2.61%. Seth Klarman would see a short-term advantage if real fundamentals remain intact.
17.79%
Operating cash flow growth exceeding 1.5x Biotechnology median of 0.08%. Joel Greenblatt would see a strong operational advantage vs. peers.
19.38%
CapEx growth of 19.38% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or upgrades behind the difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
99.99%
Growth of 99.99% while Biotechnology median is zero at 0.00%. Walter Schloss questions intangible or special projects explaining that difference.
98.29%
Investing flow of 98.29% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or deals prompting that difference.
No Data
No Data available this quarter, please select a different quarter.
684.38%
Issuance growth of 684.38% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or acquisitions financed by new shares.
No Data
No Data available this quarter, please select a different quarter.